SBRT With Atezo/Bev for HCC

Last updated: February 7, 2025
Sponsor: Abramson Cancer Center at Penn Medicine
Overall Status: Active - Recruiting

Phase

1

Condition

Digestive System Neoplasms

Carcinoma

Liver Disorders

Treatment

SBRT + atezolizumab and bevacizumab

Clinical Study ID

NCT05488522
851667
851667
  • Ages 18-99
  • All Genders

Study Summary

A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subjects must have hepatocellular carcinoma (HCC) that is not amenable tocurative-intent surgical or ablation (where surgery or ablation are not indicateddue to disease extent, co-morbidities, or other technical reasons) and systemictherapy is indicated.

Exclusion

Exclusion Criteria:

Study Design

Total Participants: 18
Treatment Group(s): 1
Primary Treatment: SBRT + atezolizumab and bevacizumab
Phase: 1
Study Start date:
September 01, 2022
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania 19104-4283
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.